NCI Taps Protagen Biomarker Technology for Immuno-Oncology Studies

February 3, 2017
NCI Taps Protagen Biomarker Technology for Immuno-Oncology Studies
Source: extender01/Getty Images

The National Cancer Institute (NCI) recently completed a material transfer agreement with German autoantibody screening and diagnostic developer Protagen AG, for the use of Protagen’s SeroTag immune system profile technology. The collaboration will be led by Jeffrey Schlom, Ph.D., chief of the laboratory of tumor Immunology and biology at the NCI’s Center for Cancer Research.

Under the agreement, NCI will provide patient samples to Protagen for analysis using the SeroTag platform. The two organizations will collaborate on the analysis and interpretation of the data derived from the tissue analysis in an effort to identify biomarkers that predict therapy responsiveness, to monitor patients receiving immunotherapies, and for early detection of immune-related adverse events (irAEs). The research will focus initially on checkpoint inhibitors, methods of therapeutic vaccination, and combination therapies.

“Our unique and innovative SeroTag technology has already proven that it can be used to accurately monitor the status of patients with autoimmune disease and segregate these complex diseases in homogeneous patient groups with the potential to predict treatment response,” said Dr. Peter Schulz-Knappe, Protagen’s chief scientific officer, in a prepared statement. “Given the links between immunotherapy and autoimmune disease, it will be a natural extension to apply our approach to immuno-oncology and address some of the most pressing questions and challenges in the field.”

According to Dr. Georg Lautscham, chief business officer with Protagen, leveraging the SeroTag technology for immuno-oncology studies is a natural extension of the technology’s capabilities.

“Protagen has already shown that SeroTag can be used to accurately monitor the status of patients with autoimmune disease, and segregate these complex diseases into homogeneous disease sub-groups with the potential to predict treatment response,” Dr. Lautscham said. “Given the link between immuno-oncology and autoimmune disease it is interesting to utilize SeroTag in this collaboration.”

Dr. Lautscham further notes that Protagen’s core expertise in monitoring the immune system in autoimmune disease will provide the basis for monitoring cancer patients receiving immune therapy to both predict response to specific drugs, while also potentially preventing administering drugs to patients with a likelihood of an immune-related adverse event.

“Despite the fact that oncology is the most advanced field with regards to precision medicine and CDx, the field of immuno-oncology is lagging behind in this context, demonstrating a shortage of biomarkers and CDx,” said Dr. Lautscham. “One of the explanations may be that in immuno-oncology novel medicines are not treating the tumor per se but we are boosting the immune system. Hence, the traditional biomarkers, e.g. mutations, which are normally key indicators used in oncology, are not able to predict response and adverse events.”

Dr. Lautscham added that Protagen’s ability to monitor the B-Cell arm of the immune system will be especially helpful in both detecting whether a particular drug has activated the immune system, and whether the extent of that activation could lead to an irAE. “We envisage offering this approach and technology to different sorts of immune-system-related therapies, such as checkpoint inhibition, and therapeutic vaccination, to all interested players in the field,” he concluded.

×

Oops! Please type your email in the following format: yourname@example.com.

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.